- Report of Foreign Issuer (6-K)
September 23 2009 - 5:09AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of September 2009
Commission File Number: 000-51440
CHINA MEDICAL TECHNOLOGIES, INC.
(Translation of registrants name into
English)
No. 24 Yong Chang North Road
Beijing Economic-Technological Development Area
Beijing 100176
Peoples Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F
X
Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
No
X
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
N/A
CHINA MEDICAL TECHNOLOGIES, INC.
Form 6-K
TABLE OF CONTENTS
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
CHINA MEDICAL TECHNOLOGIES, INC
|
|
|
By:
|
|
/s/ Takyung (Sam) Tsang
|
Name:
|
|
Takyung (Sam) Tsang
|
Title:
|
|
Chief Financial Officer
|
Date: September 23, 2009
3
Exhibit 99.1
China Medical Technologies Announces US$30 Million Share Repurchase Program
Beijing, China, September 18, 2009 - China Medical Technologies, Inc. (the Company) (Nasdaq: CMED), a leading China-based medical device company that
develops, manufactures and markets advanced in-vitro diagnostic products, today announced that its board of directors (the Board) approved a share repurchase program on September 17, 2009.
The Board has authorized the Company to repurchase up to US$30 million worth of its outstanding American Depositary Shares (ADSs) for a period of one year,
commencing on October 1, 2009. Under the terms of the program, repurchases may be made from time to time on the open market at prevailing market prices or in block trades, in accordance with the Safe Harbor requirements of Rule
10b-18 under the U.S. Securities Exchange Act of 1934, as amended (the Exchange Act). The Company may effect the repurchases pursuant to a 10b5-1 plan (which allows the Company to repurchase its ADSs during periods in which it may be in
possession of material non-public information) or otherwise. The timing and extent of any repurchase will depend upon market conditions, the trading price of ADSs and other factors, and subject to the restrictions relating to volume, price and
timing under applicable laws and regulations. The Company expects to implement this share repurchase program in a manner consistent with market conditions and the interest of the shareholders. The Companys Board will review this share
repurchase program periodically, and may authorize adjustment of its terms and size accordingly. The program may be suspended or discontinued at any time. The Company plans to fund repurchases made under this program from its available cash balance.
The record date for the Companys ADS holders for the declared cash dividend of US$0.55 per ADS is September 30, 2009.
About China Medical Technologies, Inc.
China Medical Technologies is
a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent
in situ
Hybridization (FISH) technology and
Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit
www.chinameditech.com
.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such
as will, expects, anticipates, future,
4
intends, plans, believes, estimates and similar statements. Such statements involve certain risks and
uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Companys filings with the U.S. Securities and Exchange
Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Contacts
Winnie Yam
Tel: 852-2511-9808
Email:
IR@chinameditech.com
5
China Medical (NASDAQ:CMED)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Medical (NASDAQ:CMED)
Historical Stock Chart
From Jul 2023 to Jul 2024